Dr. Kim Tan

Dr. Kim Tan is the Chairman of SpringHill Management, a private fund management company specialising in biotech and social venture capital investments. He has been a pioneer of social impact investing for over 20 years and is a partner of several social impact funds including Inqo Investments (South Africa), Novastar Ventures (Kenya), and Garden Impact Investment (Singapore), where he chairs their Investment Committees. He is the co-founder of the Transformational Business Network, and a trustee of the John Templeton Foundation and the Templeton Religion Trust.

He was an advisor to Johnson & Johnson Impact Ventures and a former trustee of the Centre for Enterprise, Markets & Ethics (Oxford). He was the founding chairman of NCI Cancer Hospital (Malaysia) and the inventor of the sheep monoclonal antibodies licensed to major diagnostic companies. He developed the first rapid tests for Salmonella in chickens and for the atrazine pesticide in drinking water. He was the former Chairman of the Surrey & Hants Innovation Growth Team, former board member of the APEC Life Science Innovation Forum, and the Saracens Rugby Club.

Dr. Kim is a Pro-Chancellor of Surrey University (UK) and a Fellow of the Royal Society of Medicine (UK). He has a PhD in Biochemistry and 3 post-doctoral fellowships from the Medical Research Council (UK). He was conferred a ‘Dato’ by the Governor of Penang (2007), and he was the recipient of the Guildford Roll of Honour (2014) and the Beacon Award for Impact Investment (2017).